Kaplan-Meier estimates of OS stratified by treatment group in patients diagnosed after May 2013.</p
<p>Kaplan-Meier estimates of mortality (a) and lost to follow-up (b) stratified by HIV status.</p
<p>Kaplan-Meier estimates according to categorical age, tumor size, NLR and PLR on DFS (a, b, c, d) ...
<p>Kaplan-Meier estimates of survival curves for patients with advanced lung cancer stratified into ...
Kaplan Meier estimates of overall survival (OS) in patients with (IRSLs+) or without immune relate s...
<p>Kaplan-Meier estimates of the cumulative proportion of patients starting ART by 30 days from ADE ...
<p>The median survival of PFS is 12.6 months and the median OS was not yet reached.</p
Stage-stratified Kaplan-Meier estimates of OS and PFS demonstrate long delays in chemotherapy (decre...
<p>Kaplan-Meier estimates of cumulative risk of having end-stage renal disease (ESRD) by treatment t...
<p>The Kaplan–Meier curves show the OS of the combined and monotherapy groups for propensity-matched...
<p>The median OS for all patients was 17.9 months (95% CI: 16.3–23.9) and the median PFS for all pat...
Kaplan-Meier survival estimate of treatment outcomes by 12 months post RR/MDR-TB treatment initiatio...
<p>Kaplan-Meier estimates of Overral survival and disease-free survival for patients receiving with ...
<p>Kaplan-Meier analyses of OS considering a molecular prognostic model and N-stage in generation an...
<p>Kaplan-Meier curve estimates adjusted for age, sex, PS and co-morbidity by treatments received: (...
<p>Median OS of treated patients was 234 days, and one-year OS (95% CI) was 33.3% (10.3–58.8%).</p
<p>Kaplan-Meier estimates of mortality (a) and lost to follow-up (b) stratified by HIV status.</p
<p>Kaplan-Meier estimates according to categorical age, tumor size, NLR and PLR on DFS (a, b, c, d) ...
<p>Kaplan-Meier estimates of survival curves for patients with advanced lung cancer stratified into ...
Kaplan Meier estimates of overall survival (OS) in patients with (IRSLs+) or without immune relate s...
<p>Kaplan-Meier estimates of the cumulative proportion of patients starting ART by 30 days from ADE ...
<p>The median survival of PFS is 12.6 months and the median OS was not yet reached.</p
Stage-stratified Kaplan-Meier estimates of OS and PFS demonstrate long delays in chemotherapy (decre...
<p>Kaplan-Meier estimates of cumulative risk of having end-stage renal disease (ESRD) by treatment t...
<p>The Kaplan–Meier curves show the OS of the combined and monotherapy groups for propensity-matched...
<p>The median OS for all patients was 17.9 months (95% CI: 16.3–23.9) and the median PFS for all pat...
Kaplan-Meier survival estimate of treatment outcomes by 12 months post RR/MDR-TB treatment initiatio...
<p>Kaplan-Meier estimates of Overral survival and disease-free survival for patients receiving with ...
<p>Kaplan-Meier analyses of OS considering a molecular prognostic model and N-stage in generation an...
<p>Kaplan-Meier curve estimates adjusted for age, sex, PS and co-morbidity by treatments received: (...
<p>Median OS of treated patients was 234 days, and one-year OS (95% CI) was 33.3% (10.3–58.8%).</p
<p>Kaplan-Meier estimates of mortality (a) and lost to follow-up (b) stratified by HIV status.</p
<p>Kaplan-Meier estimates according to categorical age, tumor size, NLR and PLR on DFS (a, b, c, d) ...
<p>Kaplan-Meier estimates of survival curves for patients with advanced lung cancer stratified into ...
DOI
Add to ORKG